Marshall Wace, LLP Cardiff Oncology, Inc. Transaction History
Marshall Wace, LLP
- $63.3 Billion
- Q1 2024
A detailed history of Marshall Wace, LLP transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 434,582 shares of CRDF stock, worth $903,930. This represents 0.0% of its overall portfolio holdings.
Number of Shares
434,582Holding current value
$903,930% of portfolio
0.0%Shares
5 transactions
Others Institutions Holding CRDF
# of Institutions
86Shares Held
8.48MCall Options Held
798KPut Options Held
39.2K-
Vanguard Group Inc Valley Forge, PA1.92MShares$4 Million0.0% of portfolio
-
Laurion Capital Management LP New York, NY929KShares$1.93 Million0.04% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny683KShares$1.42 Million0.0% of portfolio
-
Black Rock Inc. New York, NY677KShares$1.41 Million0.0% of portfolio
-
Mai Capital Management551KShares$1.15 Million0.03% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $90.1M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...